Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
| ▸ | MAP2 | P11137 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | HTR7 | P34969 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | HTR5A | P47898 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 3/20 | 0.42 |
| ▸ | HTR1D | P28221 | 2/20 | 0.42 |
| ▸ | HTR1B | P28222 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR1E | P28566 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929632 | 0.86 | CSF1R (0.43) | HTR2CHTR2ACSF1RGRM2 | |
| SCHEMBL9929605 | 0.79 | HTR1A (0.50) | PLGPLAUPLATHTR1AHTR2C | |
| SCHEMBL9930222 | 0.77 | CNR2 (0.47) | MAP2CDC7SIRT6GRM2 | |
| SCHEMBL22732085 | 0.75 | POLQ (0.51) | IKBKBCSF1RSMN1; SMN2CDC7HSP90AA1 | |
| SCHEMBL22732273 | 0.74 | NNMT (0.52) | IKBKBCDC7SIRT6HTT | |
| SCHEMBL22732240 | 0.73 | CCNT1 (0.47) | MAP2IKBKBCSF1RCDC7HTT | |
| SCHEMBL9929435 | 0.73 | CCNT1 (0.52) | MAP2GRM2 | |
| SCHEMBL22731850 | 0.71 | POLQ (0.58) | IKBKBCSF1RCDC7 | |
| SCHEMBL29574862 | 0.71 | POLQ (0.58) | IKBKBCSF1RCDC7 | |
| SCHEMBL29694876 | 0.71 | POLQ (0.58) | IKBKBCSF1RCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2473502-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2012-07-11 | — | — | EP | claimed |
| EP-2473502-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | PLG 3962/4885PLAU 3672/4885PLAT 2876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.